Quotes 5-day view Delayed Nasdaq
01/11/2021
01/12/2021
01/13/2021
01/14/2021
01/15/2021
Date
107.59(c)
108.4(c)
102.7(c)
100.85(c)
99(c)
Last
104 063
102 490
145 866
103 780
103 987
Volume
+0.42% +0.75% -5.26% -1.80% -1.83% Change
Sales 2020
-
-
-
Net income 2020
-67,9 M - -
Net cash position 2020
171 M - -
P/E ratio 2020
-38,6x
Yield 2020
-
Sales 2021
-
-
-
Net income 2021
-110 M - -
Net cash position 2021
212 M - -
P/E ratio 2021
-24,7x
Yield 2021
-
Capitalization
2 654 M 2 654 M -
EV / Sales 2020
-
EV / Sales 2021
-
Nbr of Employees
19
Free-Float
85,5%
Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to address disabling neuropsychiatric conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in...
Notations Surperformance© of Karuna Therapeutics, Inc.
Trading Rating : Investor Rating : -
All news about KARUNA THERAPEUTICS, INC.
News in other languages on KARUNA THERAPEUTICS, INC.
- No features available -
Analyst Recommendations on KARUNA THERAPEUTICS, INC.
Chart KARUNA THERAPEUTICS, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends KARUNA THERAPEUTICS, INC.
Short Term Mid-Term Long Term Trends Neutral Bullish Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
12
Average target price
130,08 $
Last Close Price
99,00 $
Spread / Highest target
64,6%
Spread / Average Target
31,4%
Spread / Lowest Target
16,2%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
